Answer a few questions using Lilly Trial Connect to find which Lilly trials may be the best fit for you or your loved one.
Answer a few questions using Lilly Trial Connect to find which Lilly trials may be the best fit for you or your loved one.

Find a Lilly Clinical Trial

11  Enrolling
40  Total Trials
CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma (CAMPFIRE)
Enrolling
Conditions: Ewing's Sarcoma
Trial Name
CAMPFIRE
Drugs: Abemaciclib (LY2835219)
Age
1 year - 39 years
Phase
II
A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) (LIBRETTO-432)
Enrolling
Conditions: Non-Small Cell Lung Cancer
Trial Name
LIBRETTO-432
Drugs: Selpercatinib
Age
≥18 years
Phase
III
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer (EMBER-4)
Enrolling
Conditions: Breast Cancer
Trial Name
EMBER-4
Drugs: Anastrozole, Exemestane, Imlunestrant, Letrozole, Tamoxifen
Age
≥18 years
Phase
III
A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors (PIKASSO-01)
Enrolling
Conditions: Breast Cancer, Advanced Solid Tumors
Trial Name
PIKASSO-01
Drugs: LOXO-783
Age
≥18 years
Phase
I
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
Enrolling
Conditions: Solid tumors
Drugs: LY4101174
Age
≥18 years
Phase
I
A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lym...
Enrolling
Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Trial Name
BRUIN CLL-322
Drugs: Pirtobrutinib, Rituximab, Venetoclax
Age
≥18 years
Phase
III
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) ...
Enrolling
Conditions: Chronic Lymphocytic Leukemia, B-cell Leukemias, Small Lymphocytic Lymphomas
Trial Name
BRUIN-CLL-314
Drugs: Pirtobrutinib, Ibrutinib
Age
≥18 years
Phase
III
A Study of LOXO-435 in Participants With Cancer With a Change in a Gene Called FGFR3
Enrolling
Conditions: Bladder Cancer, Advanced Solid Tumors
Drugs: LOX-24350 / LOXO-435, Pembrolizumab
Age
≥18 years
Phase
I
A Study of LY3537982 Plus Immunotherapy With or Without Chemotherapy in Participants With Non-Small Cell Lung Cancer (NSCLC) With a Change in ...
Enrolling
Conditions: Non-Small Cell Lung Cancer
Trial Name
SUNRAY-01
Drugs: LY3537982, Pemetrexed, Pembrolizumab, Cisplatin, Carboplatin
Age
≥18 years
Phase
III
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
Enrolling
Conditions: Lung Cancer, Advanced Solid Tumors
Drugs: LY3537982, Abemaciclib, Pembrolizumab, LY3295668, Cetuximab
Age
≥18 years
Phase
I
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Adv...
Enrolling
Conditions: Breast Cancer
Trial Name
EMBER-3
Drugs: LY3484356, Exemestane, Fulvestrant, Imlunestrant, Abemaciclib
Age
≥18 years
Phase
III

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.
29 
Completed Enrollment
40  Total Trials
Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) (BRUIN-MCL-321)
Completed Enrollment
Conditions: Mantle Cell Lymphoma
Trial Name
BRUIN-MCL-321
Drugs: Acalabrutinib, Ibrutinib, Pirtobrutinib, Zanubrutinib
Age
≥18 years
Phase
III
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors...
Completed Enrollment
Conditions: Advanced Solid Tumors
Drugs: Abemaciclib, Irinotecan, Temozolomide, Dinutuximab and GM-CSF
Age
≤21 years
Phase
II
Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small...
Completed Enrollment
Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Trial Name
BRUIN CLL-321
Drugs: Bendamustine, Idelalisib, LOXO-305, Rituximab
Age
≥18 years
Phase
III
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer (monarchE)
Completed Enrollment
Conditions: Breast Cancer
Trial Name
monarchE
Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Age
≥18 years
Phase
III
A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors (PACT)
Completed Enrollment
Conditions: Advanced Solid Tumor
Trial Name
PACT
Drugs: Ramucirumab, Abemaciclib, Merestinib, LY3300054
Age
≥18 years
Phase
I
Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment
Completed Enrollment
Conditions: Prostate Cancer
Drugs: Abemaciclib, Darolutamide, LHRH agonist/antagonist
Age
≥18 years
Phase
I
CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor (CAMPFIRE)
Completed Enrollment
Conditions: Desmoplastic Small Round Cell Tumor
Trial Name
CAMPFIRE
Drugs: Cyclophosphamide, Ramucirumab, Vinorelbine
Age
12 months - 29 years
Phase
II
A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer (JUNIPER)
Completed Enrollment
Conditions: Non-Small Cell Lung Cancer
Trial Name
JUNIPER
Drugs: Abemaciclib, Erlotinib
Age
≥18 years
Phase
III
A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer (CYCLONE 2)
Completed Enrollment
Conditions: Prostate Cancer
Trial Name
CYCLONE 2
Drugs: Abemaciclib, Abiraterone Acetate, Prednisone
Age
≥18 years
Phase
III
A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to ...
Completed Enrollment
Conditions: Prostate Cancer
Trial Name
CYCLONE 3
Drugs: Abemaciclib, Abiraterone, LY2835219, Prednisone, Prednisolone
Age
≥18 years
Phase
III
A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma (ANNOUNCE)
Completed Enrollment
Conditions: Soft Tissue Sarcoma
Trial Name
ANNOUNCE
Drugs: Olaratumab/Placebo, Doxorubicin
Age
≥18 years
Phase
III
A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer (Next MONARCH 1)
Completed Enrollment
Conditions: Breast Cancer
Trial Name
Next MONARCH 1
Drugs: Abemaciclib, Tamoxifen, Prophylactic Loperamide
Age
≥18 years
Phase
II
A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer (MONARCH plus)
Completed Enrollment
Conditions: Breast Cancer
Trial Name
MONARCH plus
Drugs: Abemaciclib, Anastrozole, Letrozole, Fulvestrant
Age
≥18 years
Phase
III
Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer (postMONARCH)
Completed Enrollment
Conditions: Breast Cancer
Trial Name
postMONARCH
Drugs: Abemaciclib, Fulvestrant
Age
≥18 years
Phase
III
A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Smal...
Completed Enrollment
Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Trial Name
BRUIN CLL-313
Drugs: Bendamustine, Pirtobrutinib, Rituximab
Age
≥18 years
Phase
III
A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment (JUVE-BASIS)
Completed Enrollment
Conditions: Lung Cancer, Thyroid Cancer and other Solid Tumors
Trial Name
JUVE-BASIS
Drugs: LOXO-260
Age
≥12 years
Phase
I
A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer (EMBER)
Completed Enrollment
Conditions: Breast Cancer, Endometrial Cancer
Trial Name
EMBER
Drugs: LY3484356, Abemaciclib
Age
≥18 years
Phase
I
A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer
Completed Enrollment
Conditions: Breast Cancer, Non-Small Cell Lung Cancer
Drugs: Abemaciclib, Pembrolizumab
Age
≥18 years
Phase
I
A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma
Completed Enrollment
Conditions: Neuroblastoma
Drugs: LY3295668 Erbumine, Topotecan, Cyclophosphamide
Age
2 - 21 years
Phase
I
A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread
Completed Enrollment
Conditions: Breast Cancer
Drugs: LY2835219, Letrozole, Anastrozole, Tamoxifen, Exemestane
Age
≥18 years
Phase
I
A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer (LIBRETTO-431)
Completed Enrollment
Conditions: Non-small Cell Lung Cancer
Trial Name
LIBRETTO-431
Drugs: Carboplatin, Cisplatin, Pembrolizumab, Pemetrexed, Selpercatinib
Age
≥18 years
Phase
III
A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic N...
Completed Enrollment
Conditions: Non-Small Cell Lung Cancer
Trial Name
RELAY
Drugs: Ramucirumab, Erlotinib
Age
≥18 years
Phase
III
A Study of LY3200882 in Participants With Solid Tumors
Completed Enrollment
Conditions: Advanced Solid Tumor
Drugs: LY3200882
Age
≥18 years
Phase
I
A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast Cancer (eMonarcHER)
Completed Enrollment
Conditions: Breast Cancer
Trial Name
eMonarcHER
Drugs: Abemaciclib Plus Hormone Therapy
Age
≥18 years
Phase
III
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
Completed Enrollment
Conditions: Advanced Solid Tumor
Drugs: Ramucirumab, cisplatin, gemcitabine, Merestinib
Age
≥18 years
Phase
II
A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)
Completed Enrollment
Conditions: Medullary Thyroid Cancer
Trial Name
LIBRETTO-531
Drugs: Selpercatinib, Cabozantinib, Vandetanib
Age
≥12 years
Phase
III
Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations (I9Y-OX-JDHB)
Completed Enrollment
Conditions: Leukemia - AML, Leukemia - CML, Myelodysplastic Syndrome
Trial Name
I9Y-OX-JDHB
Drugs: LY3410738
Age
≥18 years
Phase
I
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Completed Enrollment
Conditions: Advanced Solid Tumor
Drugs: LY3410738
Age
≥18 years
Phase
I
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
Completed Enrollment
Conditions: Blood Cancers
Drugs: LOXO-338 / LY3847429, Pirtobruitinib
Age
≥18 years
Phase
I